$ 14.51
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
In Guru Portfolios
Data is available to registered users only
Data is available to registered users only
Portfolio Weight (%)
Data is available to registered users only
Change
Data is available to registered users only
Fund
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Portfolio Weight (%)
Data is available to registered users only
Change
Data is available to registered users only
Fund
Data is available to registered users only
Data is available to registered users only
Data is available to registered users only
Portfolio Weight (%)
Data is available to registered users only
Change
Data is available to registered users only
Fund
Data is available to registered users only
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
About
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Target Price
The average target price of BHVN is 23.3 and suggests 62.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr
Data is available to registered users only